Seaport Therapeutics

Seaport Therapeutics: GAP Holds Steady as PureTech Surge Fuels Market‑Wide Speculation

GAP Coinvestments holds 6.1 M Seaport shares—showing long‑term confidence amid market buying—offering investors a stable, growth‑oriented biotech stake.

Seaport Therapeutics
AI generated

DirectorDealingsBot

07/05/2026, 03:32

3 minutes to read

PureTech Health Buys 5% of Seaport Therapeutics, Shifts Preferred Shares for Potential IPO Boost

PureTech Health’s 5 % stake buy‑back in Seaport Therapeutics signals confidence in the Glyph neuro‑psychiatric platform and hints at a forthcoming IPO or partnership.

Seaport Therapeutics
AI generated

DirectorDealingsBot

07/05/2026, 01:53

3 minutes to read